In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3075-3080

  Masse, Sherie ^a   Lu, Xiaozhi ^b   Dekhtyar, Tatyana ^a   Lu, Liangjun ^a   Koev, Gennadiy ^a   Gao, Feng ^b   Mo, Hongmei ^a   Kempf, Dale ^a   Bernstein, Barry ^a   Hanna, George J ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DRUG RESISTANCE, VIRAL; HIV CORE PROTEIN P24; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; PYRIMIDINONES; RNA-DIRECTED DNA POLYMERASE; VIRUS REPLICATION;

EID: 35948950183     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00146-07     Document Type: Article

References (28)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Bally, F., R. Martinez, S. Peters, P. Sudre, and A. Telenti. 2000. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retrovir. 16:1209-1213.
3. Benson, C. A., S. G. Deeks, S. C. Brun, R. M. Gulick, J. J. Eron, H. A. Kessler, R. L. Murphy, C. Hicks, M. King, D. Wheeler, J. Feinberg, R. Stryker, P. E. Sax, S. Riddler, M. Thompson, K. Real, A. Hsu, D. Kempf, A. J. Japour, and E. Sun. 2002. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. 185:599-607.
4. Carrillo, A., K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:7532-7541.
5. Clavel, F., M. Guyader, D. Guetard, M. Salle, L. Montagnier, and M. Alizon. 1986. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324:691-695.
6. da Silva, B., F. McMillan, C. Hicks, J. Eron, P. Wolfe, R. Gulick, M. Glesby, M. Thompson, C. Benson, A. C. White, M. Albrecht, H. Kessler, K. Niemi, K. King, D. Calhoun, M. King, G. Hanna, and S. Brun. 2005. Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects, abstr. PE7.9/3. Abstr. 10th Eur. AIDS Conf.
7. de Mendosza, C., L. Valer, L. Bacheler, T. Pattery, A. Corral, and V. Soriano. 2006. Prevalence of the HIV-1 protease 147A in clinical practice and association with lopinavir resistance. AIDS 20:1071-1073.
8. Friend, J., N. Parkin, T. Liegler, J. N. Martin, and S. G. Deeks. 2004. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18:1965-1966.
9. Isaka, Y., S. Miki, S. Kawauchi, A. Suyama, H. Sugimoto, A. Adachi, T. Miura, M. Hayami, O. Yoshie, T. Fujiwara, and A. Sato. 2001. A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch. Virol. 146:743-755.
10. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
11. Kagan, R. M., M. D. Shenderovich, P. N. Heseltine, and K. Ramnarayan. 2005. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 14:1870-1878.
12. Kanki, P., F. Barin, and M. Essex. 1988. Antibody reactivity to multiple HIV-2 isolates, abstr. 1659. Abstr. Int. Conf. AIDS.
13. Kempf, D., J. Isaacson, M. King, S. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
14. Mo, H., M. S. King, K. King, A Molla, S. Brun, and D. J. Kempf. 2005. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79:3329-3338.
15. Mukhopadhyay, C., G. Nath, A. K. Gulati, and S. C. Mohapatra. 2001. Prevalence of HIV among low and high risk population of eastern part of northern India. J. Commun. Dis. 33:136-142.
16. Mullins, C., G. Eisen, S. Popper, A. D. Sarr, J. L. Sankale, J. J. Berger, S. B. Wright, H. R. Chang, G. Coste, T. P. Cooley, P. Rice, P. R. Skolnik, M. Sullivan, and P. J. Kanki. 2004. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin. Infect. Dis. 38:1771-1779.
17. Owen, S. M., D. Ellenberger, M. Rayfield, S. Wiktor, P. Michel, M. H. Grieco, F. Gao, B. H. Hahn, and R. B. Lal. 1998. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 72:5425-5432.
18. Pieniazek, D., M. Rayfield, D. J. Hu, J. N. Nkengasong, V. Soriano, W. Heneine, C. Zeh, S. M. Agwale, C. Wambebe, L. Odama, and S. Z. Wiktor. 2004. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 18:495-502.
19. Rodes, B., J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano. 2006. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57:709-713.
20. Rodes, B., C. Toro, V. Jimenez, and V. Soriano. 2005. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin. Infect. Dis. 41:e19-e21.
21. Rodes, B., C. Toro, J. A. Sheldon, V. Jimenez, K. Mansinho, and V. Soriano. 2006. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 20:127-129.
22. Rodes, B., A. Holguin, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. Gonzalez-Lahoz. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
23. Schulz, T. F., D. Whitby, J. G. Hoad, T. Corrah, H. Whittle, and R. A. Weiss. 1990. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J. Virol. 64:5177-5182.
24. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C. M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. M. Leonard, J. J. Plattner, and D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
25. Shanmugam, V., W. M. Switzer, J. N. Nkengasong, G. Garcia-Lerma, T. A. Green, E. Ekpini, M. Sassan-Morokro, F. Antunes, K. Manshino, V. Soriano, S. Z. Wiktor, and W. Heneine. 2000. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J. Acquir. Immune Defic. Syndr. 24:257-263.
26. Verheyen, J., E. Litau, T. Sing, M. Däumer, M. Balduin, M. Oette, G. Fätkenheuer, J. K. Rockstroh, V. Schuldenzucker, D. Hoffman, H. Pfister, and R. Kaiser. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naïve and therapy-experienced patients. Antivir. Ther. 11:879-887.
27. Witvrouw, M., C. Pannecouque, W. M. Switzer, T. M. Folks, E. De Clercq, and W. Heneine. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.
28. Witvrouw, M., C. Pannecouque, K. Van Laethem, J. Desmyter, E. De Clercq, and A. M. Vandamme. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13:1477-1483.